{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T20:16:54Z","timestamp":1777148214261,"version":"3.51.4"},"reference-count":30,"publisher":"Tohoku University Medical Press","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2023]]},"DOI":"10.1620\/tjem.2023.j016","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T22:11:13Z","timestamp":1677708673000},"page":"29-34","source":"Crossref","is-referenced-by-count":7,"title":["Therapeutic Drug Monitoring of Blood Sirolimus and Tacrolimus Concentrations for Polypharmacy Management in a Lymphangioleiomyomatosis Patient Taking Two Cytochrome P450 3A Inhibitors"],"prefix":"10.1620","volume":"260","author":[{"given":"Masaki","family":"Kumondai","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Tohoku University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Tohoku University Hospital"},{"name":"Faculty of Pharmaceutical Sciences, Tohoku University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Mizuguchi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Tohoku University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagomi","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Tohoku University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Ui","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Tohoku University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Hirama","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Tohoku University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Tohoku University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Tohoku University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Tohoku University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamitsu","family":"Maekawa","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Tohoku University Hospital"},{"name":"Faculty of Pharmaceutical Sciences, Tohoku University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nariyasu","family":"Mano","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Tohoku University Hospital"},{"name":"Faculty of Pharmaceutical Sciences, Tohoku University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"622","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Ando, K., Okada, Y., Akiba, M., Kondo, T., Kawamura, T., Okumura, M., Chen, F., Date, H., Shiraishi, T., Iwasaki, A., Yamasaki, N., Nagayasu, T., Chida, M., Inoue, Y., Hirai, T., et al.   (2016)  Lung transplantation for lymphangioleiomyomatosis in Japan.  <i>PLoS One<\/i>, 11, e0146749.","DOI":"10.1371\/journal.pone.0146749"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Barve, A., Kovacs, S.J., Ke, J., Crabbe, R., Grosgurin, P., Menetrey, A., Nicolas-Metral, V., Dabovic, K., Dole, K., Zhang, J., Praestgaard, J., Sunkara, G. &amp; Stein, D. (2015)  The effects of CYP3A4 induction and inhibition on the pharmacokinetics of alisporivir in humans.  <i>Clin. Pharmacol. Drug Dev.<\/i>, 4, 25-32.","DOI":"10.1002\/cpdd.114"},{"key":"3","unstructured":"FDA (United States Food &amp; Drug Administration) (2022)  Drug development and drug interactions | Table of substrates, inhibitors and inducers.  https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers  [<i>Accessed<\/i>: December 12, 2022]"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Ferrans, V.J., Yu, Z.X., Nelson, W.K., Valencia, J.C., Tatsuguchi, A., Avila, N.A., Riemenschn, W., Matsui, K., Travis, W.D. &amp; Moss, J. (2000)  Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features.  <i>J. Nippon Med. Sch.<\/i>, 67, 311-329.","DOI":"10.1272\/jnms.67.311"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Gijsen, V.M., van Schaik, R.H., Elens, L., Soldin, O.P., Soldin, S.J., Koren, G. &amp; de Wildt, S.N. (2013)  CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients.  <i>Pharmacogenomics<\/i>, 14, 1027-1036.","DOI":"10.2217\/pgs.13.80"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Hendriks, D.F.G., Vorrink, S.U., Smutny, T., Sim, S.C., Nordling, A., Ullah, S., Kumondai, M., Jones, B.C., Johansson, I., Andersson, T.B., Lauschke, V.M. &amp; Ingelman-Sundberg, M. (2020)  Clinically relevant cytochrome P450 3A4 induction mechanisms and drug screening in three-dimensional spheroid cultures of primary human hepatocytes.  <i>Clin. Pharmacol. Ther.<\/i>, 108, 844-855.","DOI":"10.1002\/cpt.1860"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Huang, S.M., Strong, J.M., Zhang, L., Reynolds, K.S., Nallani, S., Temple, R., Abraham, S., Habet, S.A., Baweja, R.K., Burckart, G.J., Chung, S., Colangelo, P., Frucht, D., Green, M.D., Hepp, P., et al.   (2008)  New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process.  <i>J. Clin. Pharmacol.<\/i>, 48, 662-670.","DOI":"10.1177\/0091270007312153"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Isoherranen, N., Kunze, K.L., Allen, K.E., Nelson, W.L. &amp; Thummel, K.E. (2004)  Role of itraconazole metabolites in CYP3A4 inhibition.  <i>Drug Metab. Dispos.<\/i>, 32, 1121-1131.","DOI":"10.1124\/dmd.104.000315"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Kikuchi, M., Shigeta, K., Tanaka, M., Takasaki, S., Akiba, M., Oishi, H., Sado, T., Matsuda, Y., Noda, M., Okada, Y., Mano, N. &amp; Yamaguchi, H. (2019)  Estimation of blood sirolimus concentration based on tacrolimus concentration\/dose normalized by body weight ratio in lung transplant patients.  <i>Ther. Drug Monit.<\/i>, 41, 615-619.","DOI":"10.1097\/FTD.0000000000000649"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Kumondai, M., Gutierrez Rico, E.M., Hishinuma, E., Ueda, A., Saito, S., Saigusa, D., Tadaka, S., Kinoshita, K., Nakayoshi, T., Oda, A., Abe, A., Maekawa, M., Mano, N., Hirasawa, N. &amp; Hiratsuka, M. (2021)  Functional characterization of 40 CYP3A4 variants by assessing midazolam 1&apos;-hydroxylation and testosterone 6beta-hydroxylation.  <i>Drug Metab. Dispos.<\/i>, 49, 212-220.","DOI":"10.1124\/dmd.120.000261"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Kuypers, D.R., Claes, K., Evenepoel, P., Maes, B., Vandecasteele, S., Vanrenterghem, Y., Van Damme, B. &amp; Desmet, K. (2005)  Drug interaction between itraconazole and sirolimus in a primary renal allograft recipient.  <i>Transplantation<\/i>, 79, 737.","DOI":"10.1097\/01.TP.0000147462.86886.F3"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Lesche, D., Sigurdardottir, V., Setoud, R., Oberhansli, M., Carrel, T., Fiedler, G.M., Largiader, C.R., Mohacsi, P. &amp; Sistonen, J. (2014)  CYP3A5*3 and POR*28 genetic variants influence the required dose of tacrolimus in heart transplant recipients.  <i>Ther. Drug Monit.<\/i>, 36, 710-715.","DOI":"10.1097\/FTD.0000000000000080"},{"key":"13","doi-asserted-by":"crossref","unstructured":"MacDonald, A., Scarola, J., Burke, J.T. &amp; Zimmerman, J.J. (2000)  Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus.  <i>Clin. Ther.<\/i>, 22 Suppl B, B101-121.","DOI":"10.1016\/S0149-2918(00)89027-X"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Matsuda, Y., Nakagawa, S., Yano, I., Masuda, S., Imai, S., Yonezawa, A., Yamamoto, T., Sugimoto, M., Tsuda, M., Tsuzuki, T., Omura, T., Nakagawa, T., Chen-Yoshikawa, T.F., Nagao, M., Date, H., et al.   (2022)  Effect of itraconazole and its metabolite hydroxyitraconazole on the blood concentrations of cyclosporine and tacrolimus in lung transplant recipients.  <i>Biol. Pharm. Bull.<\/i>, 45, 397-402.","DOI":"10.1248\/bpb.b21-00738"},{"key":"15","doi-asserted-by":"crossref","unstructured":"McCormack, F.X., Inoue, Y., Moss, J., Singer, L.G., Strange, C., Nakata, K., Barker, A.F., Chapman, J.T., Brantly, M.L., Stocks, J.M., Brown, K.K., Lynch, J.P. 3rd, Goldberg, H.J., Young, L.R., Kinder, B.W., et al.   (2011)  Efficacy and safety of sirolimus in lymphangioleiomyomatosis.  <i>N. Engl. J. Med.<\/i>, 364, 1595-1606.","DOI":"10.1056\/NEJMoa1100391"},{"key":"16","unstructured":"Mohammadpour, N., Elyasi, S., Vahdati, N., Mohammadpour, A.H. &amp; Shamsara, J. (2011)  A review on therapeutic drug monitoring of immunosuppressant drugs.  <i>Iran J. Basic Med. Sci.<\/i>, 14, 485-498."},{"key":"17","doi-asserted-by":"crossref","unstructured":"Niioka, T., Kagaya, H., Saito, M., Inoue, T., Numakura, K., Habuchi, T., Satoh, S. &amp; Miura, M. (2015)  Capability of utilizing CYP3A5 polymorphisms to predict therapeutic dosage of tacrolimus at early stage post-renal transplantation.  <i>Int. J. Mol. Sci.<\/i>, 16, 1840-1854.","DOI":"10.3390\/ijms16011840"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Quinney, S.K., Malireddy, S.R., Vuppalanchi, R., Hamman, M.A., Chalasani, N., Gorski, J.C. &amp; Hall, S.D. (2013)  Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin.  <i>Eur. J. Clin. Pharmacol.<\/i>, 69, 439-448.","DOI":"10.1007\/s00228-012-1339-x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Quinney, S.K., Zhang, X., Lucksiri, A., Gorski, J.C., Li, L. &amp; Hall, S.D. (2010)  Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin.  <i>Drug Metab. Dispos.<\/i>, 38, 241-248.","DOI":"10.1124\/dmd.109.028746"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Rodriguez-Antona, C., Savieo, J.L., Lauschke, V.M., Sangkuhl, K., Drogemoller, B.I., Wang, D., van Schaik, R.H.N., Gilep, A.A., Peter, A.P., Boone, E.C., Ramey, B.E., Klein, T.E., Whirl-Carrillo, M., Pratt, V.M. &amp; Gaedigk, A. (2022)  PharmVar GeneFocus: CYP3A5.  <i>Clin. Pharmacol. Ther.<\/i>, 112, 1159-1171.","DOI":"10.1002\/cpt.2563"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Rojas, L., Neumann, I., Herrero, M.J., Boso, V., Reig, J., Poveda, J.L., Megias, J., Bea, S. &amp; Alino, S.F. (2015)  Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies.  <i>Pharmacogenomics J.<\/i>, 15, 38-48.","DOI":"10.1038\/tpj.2014.38"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Rosso Felipe, C., de Sandes, T.V., Sampaio, E.L., Park, S.I., Silva, H.T. Jr. &amp; Medina Pestana, J.O. (2009)  Clinical impact of polymorphisms of transport proteins and enzymes involved in the metabolism of immunosuppressive drugs.  <i>Transplant. Proc.<\/i>, 41, 1441-1455.","DOI":"10.1016\/j.transproceed.2009.03.024"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Said, A., Garnick, J.J., Dieterle, N., Peres, E., Abidi, M.H. &amp; Ibrahim, R.B. (2006)  Sirolimus-itraconazole interaction in a hematopoietic stem cell transplant recipient.  <i>Pharmacotherapy<\/i>, 26, 289-295.","DOI":"10.1592\/phco.26.2.289"},{"key":"24","unstructured":"Scheffert, J.L. &amp; Raza, K. (2014)  Immunosuppression in lung transplantation.  <i>J. Thorac. Dis.<\/i>, 6, 1039-1053."},{"key":"25","doi-asserted-by":"crossref","unstructured":"Shirasaka, Y., Chang, S.Y., Grubb, M.F., Peng, C.C., Thummel, K.E., Isoherranen, N. &amp; Rodrigues, A.D. (2013)  Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions.  <i>Drug Metab. Dispos.<\/i>, 41, 1566-1574.","DOI":"10.1124\/dmd.112.049940"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Taveira-DaSilva, A.M. &amp; Moss, J. (2015)  Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis.  <i>Clin. Epidemiol.<\/i>, 7, 249-257.","DOI":"10.2147\/CLEP.S50780"},{"key":"27","unstructured":"The LAM Foundation (2022)  LAM Management.  https:\/\/www.thelamfoundation.org\/Healthcare-Providers\/Diagnosis-Treatment\/LAM-Management  [<i>Accessed<\/i>: December 6, 2022]"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Vanhove, T., de Jonge, H., de Loor, H., Oorts, M., de Hoon, J., Pohanka, A., Annaert, P. &amp; Kuypers, D.R.J. (2018)  Relationship between in vivo CYP3A4 activity, CYP3A5 genotype, and systemic tacrolimus metabolite\/parent drug ratio in renal transplant recipients and healthy volunteers.  <i>Drug Metab. Dispos.<\/i>, 46, 1507-1513.","DOI":"10.1124\/dmd.118.081935"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Zanger, U.M. &amp; Schwab, M. (2013)  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.  <i>Pharmacol. Ther.<\/i>, 138, 103-141.","DOI":"10.1016\/j.pharmthera.2012.12.007"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Zhang, J., Dai, Y., Liu, Z., Zhang, M., Li, C., Chen, D. &amp; Song, H. (2017)  Effect of CYP3A4 and CYP3A5 genetic polymorphisms on the pharmacokinetics of sirolimus in healthy Chinese volunteers.  <i>Ther. Drug Monit.<\/i>, 39, 406-411.","DOI":"10.1097\/FTD.0000000000000415"}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/260\/1\/260_2023.J016\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:43:24Z","timestamp":1715316204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/260\/1\/260_2023.J016\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.2023.j016","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"2023.J016"}}